ADA Scientific Sessions 2026 Abstract

Digital Programme Engagement Enhances GLP-1 Receptor Agonist Weight Loss Outcomes in Type 2 Diabetes

By Hans H. Johnson, Daniel Reisel, David Huang

Study in peopleInterventions

The paper

Hans H. Johnson, Daniel Reisel, David Huang

Bristol

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1661-P

doi.org/10.2337/db26-1661-p

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk